KULICKE AND SOFFA INDUSTRIES, INC. (KLIC): what the price assumes

In the published model solve dated 2026-Q2, anchored at $82.13, KULICKE AND SOFFA INDUSTRIES, INC. (KLIC) is priced for today's economics sustained for ~13.4 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/KLIC

Headline

FieldValue
TickerKLIC
CompanyKULICKE AND SOFFA INDUSTRIES, INC.
Current price$82.13/sh
CompositionGeneral Semiconductor 51% / Automotive & Industrial 17% / Memory 8% / APS 24%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)34.2%
Operating margin (mid-cycle)13.8%
Margin expansion (value-band)+20.4pp
Trailing margin (depressed year)6.7%
Must persist for13.4y
Multiple paid39x mid-cycle operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 11.9% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.2 years.

Reconcile: at the x-ray's 9.3% required return this reads ~8 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history+0.16σ
cohort percentile (of 190 peers)67
sustained it ~10 years at this level15%
implied end-window share0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset8.96x5expensive
Earnings7.14x3expensive
Relative1.89x3expensive
Growth1.09x3expensive

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.

Per-Model Detail (n=14)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$6.0013.69xyesFCF base $0.0B, growth 12% (input: historical growth), terminal g 4.0%, WACC 9.0%, 6yr projection
DCF Exit MultipleGrowth$76.151.08xyesExit EV/EBITDA: 59.2x / 61.2x / 63.2x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$43.551.89xyesP/E 39.18x (blended: static sector reference 22x + trailing (TTM) 79x), scenarios: 32.3x / 39.2x / 46.1x (bear / base = reference held flat / bull), EV/EBITDA 29.57x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$11.207.33xyesBV/sh $16.14, ROE (TTM) 6.4%, ke 9.3%
Two-Stage Excess ReturnAsset$9.178.96xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$75.281.09xyesRev $0.8B, growth 12% (input: historical growth; tapered), Terminal P/S: 4.7x / 5.7x / 6.7x (bear / base = today's held flat / bull, cap 12x)
Growth-Adjusted P/ERelativeno
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$36.612.24xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.19B × (1−17%) / WACC 9.0% → EPV (no growth)
Residual IncomeAsset$8.909.23xyesBV $16.14 + 5yr PV of (ROE (TTM) 6.4% − Kₑ 9.3%) × BV; BV grows 4.2%/yr
Graham NumberAsset$19.664.18xyes√(22.5 × EPS $1.06 × BVPS $16.14) — Graham's conservative floor
EV/EBITDA RelativeRelative$24.293.38xyesEBITDA $0.07B × sector EV/EBITDA 16.0x
FCF YieldEarnings$4.7017.47xyesFCF $4.3M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarnings$0.8992.28xyesEPS $1.06 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset$8.779.36xyesBV $16.14 × (ROIC 4.9% / WACC 9.0%)
P/Sales SectorRelative$72.311.14xyesRevenue $0.77B × sector P/S 5.0x
PEG Fair ValueRelativeno
Earnings YieldEarnings$11.507.14xyesEPS $1.06 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net cash$487.9m
Net debt / NOPAT (after-tax)-5.58x (net cash)
Net debt / operating income (pre-tax)-4.62x (net cash)
Interest coverage714.2x
Share count CAGR (buyback)-4.0%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 13.8%); the trailing year was depressed.

Bullet Takeaways

At $121.81 the market pays roughly 60x company-wide mid-cycle operating income for Kulicke & Soffa, an assumption that operating growth holds near its self-funding ceiling for about 19 years. Only about 15% of comparable fast-growers have sustained that pace for even a decade.

The balance sheet is the firm's strongest card: nearly $488 million in cash and investments, no debt, and a share count shrinking about 4% a year through buybacks. That cushion funds the recovery and the pivot to advanced-packaging bonding without a capital raise.

Fiscal Q2 2026 revenue jumped 21.5% sequentially to $242.6 million with adjusted EPS of $0.79 beating expectations, and management guided Q3 to about $310 million. The business is recovering off a deep cyclical trough, but the static valuation methods say the price has run far ahead of the earnings.

Bull Case

The clearest thing about Kulicke & Soffa is its balance sheet, and that balance sheet is the bull case. The company holds nearly $488 million in cash and investments against essentially no debt, with interest coverage that is academic because there is almost nothing to cover. That is an unusually strong balance sheet for a sub-$1-billion-revenue equipment maker, and what it reveals is management confidence: a board that keeps buying back stock, having repurchased shares under successive programs and authorized a new one (FY2025 10-K, accession 0000056978-25-000081), and that is funding a capacity expansion out of cash rather than dilution. The share count has shrunk about 4% a year, the cleanest possible signal that insiders think the stock is worth owning through the cycle.

That cash matters because it buys time to ride a recovery that is clearly underway. Fiscal Q2 2026 revenue rose 21.5% sequentially to $242.6 million, GAAP net income swung to $35.1 million from a year-earlier loss, and adjusted EPS of $0.79 beat the $0.67 expectation. The bookings line in the filing tells the trajectory: orders of $750.8 million in fiscal 2025 versus $431.0 million the year before, with backlog up to $245.3 million from $148.6 million (FY2025 10-K). The memory segment alone jumped 93% sequentially on NAND demand and expansion among Chinese memory packagers. A company with this much net cash does not have to chase the cycle; it can invest into it from strength.

The forward option is the advanced-packaging pivot, and management is funding it deliberately. Kulicke & Soffa is raising fiscal 2026 capex from about $12 million to $22 million to expand thermo-compression bonding capacity, targeting roughly $400 million in annual TCB system sales by early fiscal 2027, while winding down its lower-return Electronics Assembly business. TCB is the bonding technology that AI accelerators and high-bandwidth memory increasingly require, the same advanced-packaging wave lifting the whole equipment sector. Against peers like FormFactor, Allegro, and Skyworks, Kulicke & Soffa is a focused, debt-free, cash-rich way to play the packaging step, with the financial room to keep investing if the recovery extends. The balance sheet is what lets the growth story stay credible.

Bear Case

The variable with the most leverage on Kulicke & Soffa is geopolitics, and the price does not reflect that exposure. A large share of demand for ball-bonding equipment flows through Chinese assembly and test houses, the OSATs that package chips, and the company's own filing flags the Chinese government as a competitive and policy risk alongside its note that average selling prices usually decline over time due to continuous price pressure from customers, competitors, and supply-chain cost reductions (FY2025 10-K, accession 0000056978-25-000081). That is a double bind: the fastest-growing slice of demand sits in the jurisdiction most exposed to export controls and trade friction, and the pricing on the equipment erodes structurally even when units grow. A tightening of US controls on bonding equipment to China, or Chinese retaliation favoring domestic suppliers, would remove demand that may not return.

The macro cyclicality is the second exposure, and it is severe. The company states plainly that the semiconductor industry is volatile and that its operating results are adversely impacted by volatile worldwide economic conditions (FY2025 10-K). The numbers prove it: bookings nearly doubled from $431 million to $751 million in a single year, the kind of swing that runs in both directions. The recovery the bull case celebrates is the up-leg of a cycle that has a down-leg, and equipment orders can evaporate as fast as they appeared when end demand softens or customers digest capacity.

What makes those risks acute is the valuation. At $121.81 (June 27, 2026) the price embeds operating growth held near the self-funding ceiling for roughly 19 years, a duration the reverse-DCF flags as elevated, above what fundamentals comfortably support, with only about 15% of comparable fast-growers sustaining such a pace for even ten years. The asset and earnings-power methods land in the teens to low thirties; only the growth-DCF reaches the price, and it does so by extrapolating a cyclical peak. Net cash near $488 million protects the company from insolvency, but it does not protect the stock from a re-rating if the China door narrows or the cycle rolls. Buy here and you are paying a near-two-decade growth premium for a small, cyclical, China-exposed equipment maker. That is the fragility the price ignores.

Valuation

Kulicke & Soffa is the textbook case of method disagreement, and the disagreement says the price is stretched. Every static frame that values the company on what it owns or earns today lands far below $121.81: simple excess return near $11, two-stage excess return near $9, residual income near $9, the Graham Number near $20, and earnings power value near $36 even after normalizing a five-year average EBIT. Those reflect a trailing return on equity near 6% and a book value per share of $16.14. The only methods that reach the price are the growth and relative frames, the DCF exit multiple and discounted future market cap near $112, the blended relative method near $52, and they do so by extrapolating recent cyclical growth and a peak multiple.

The reverse-DCF makes the stretch explicit. Because trailing earnings are depressed by the cycle, the engine prices the company on its through-the-cycle margins, normalized operating income near $106 million on a 13.8% mid-cycle margin, and at $121.81 the market pays roughly 60x that figure. That implies operating growth held near the 25% self-funding ceiling for about 19 years, computed at a 12.4% cost of capital, with each percentage point of growth shifting the required duration by about 2.7 years.

The honest synthesis is that on normalized, through-the-cycle economics, the stock looks expensive, and the priced-in assumption is elevated rather than merely demanding. The bull case is not that the methods are wrong but that they cannot price a successful pivot to advanced-packaging TCB, the durable-compounding bet only the growth frame captures. The balance sheet, nearly $488 million of net cash and no debt, removes the downside-insolvency risk and gives the pivot room to play out. But the math is unambiguous: the price requires the recovery to become a long secular growth story, not just a cyclical bounce, and the base rate for sustaining that is low.

Catalysts

Fiscal Q2 2026 (reported spring 2026) was a strong recovery quarter: net revenue of $242.6 million, up 21.5% sequentially, GAAP net income of $35.1 million versus a year-earlier loss, and adjusted EPS of $0.79 against a $0.67 expectation. The memory segment rose 93% sequentially on NAND demand and Chinese memory-packager expansion. Management guided fiscal Q3 to about $310 million in revenue, plus or minus $20 million, with non-GAAP EPS near $1.00, a sharp sequential step up that the next print will have to validate.

The defining strategic catalyst is the advanced-packaging pivot. Kulicke & Soffa is raising fiscal 2026 capex from about $12 million to $22 million to expand thermo-compression bonding capacity and targets roughly $400 million in annual TCB system sales by early fiscal 2027, while winding down its Electronics Assembly business. Milestones on TCB design wins, capacity, and the path to that $400 million run-rate will drive the growth thesis directly over the coming quarters.

The swing factors to watch over the next 90 days are China export-control policy, since a large share of ball-bonding demand flows through Chinese assembly houses, the booking trend as a leading indicator of the cycle, and continued share buybacks against the nearly $488 million cash balance. End-market demand from AI-driven advanced packaging versus traditional commodity packaging is the mix question that determines whether the recovery is cyclical or secular.

Sources: PRNewswire (KLIC Q2 2026 results), StockTitan (Q2 2026 8-K), Yahoo Finance (Q2 2026 call), Investing.com (Q2 FY2026 slides), Quartr, StockAnalysis.

Peer Cohorts (Per Segment, With Filing Citations)

Ball Bonding Equipment (reported)

Wedge Bonding Equipment (reported)

Advanced Solutions (reported)

APS (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive KLIC report on boothcheck